Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the fourth quarter and fiscal year 2025 ended January 2, 2026.
Company Outlines Next Phase of Growth Focused on Control Acquisitions Designed to Scale Breakthrough Technology PlatformsLAKEWOOD, NJ, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc.
Genius Sports Limited ( GENI) M&A Call February 5, 2026 8:00 AM EST Hello, and welcome to today's call where Genius Sports Management will discuss its acquisition of Legend. We ask that you please ...
3 小时on MSN
Advanced Drainage Systems outlines $3.015B revenue target and highlights NDS integration ...
Q3 2026 Management View CEO D. Barbour reported strong results for the quarter, stating the company "outperformed the market ...
PRESSADVANTAGE – Stephen Twomey has published a new educational resource exploring how serious and sophisticated investors use alternative investment apps to access, organize, and monitor private ...
Heavy Equipment Category -- CEO Angrick described heavy equipment GMV growth near 30% compound quarterly rate, with strategic ...
Detailed price information for Walt Disney Company (DIS-N) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN
Micron (MU) is a top-ranked momentum stock: Should you buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
Net sales of $10.1 billion, down 13.5%, in 2025 Full year reported operating margin of 5.9% and adjusted operating margin(1) of 7.7% 2025 full year reported earnings ...
Investors closely watch Amazon’s AWS growth and margin trajectory post-Microsoft’s cloud reset, seeking proof that AI demand can offset capex challenges and sustain steady growth in the face ...
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. today reported financial results for the quarter ended December 31, 2025.
Novartis has core profit growth, buybacks, seven clinical readouts, a 5% dividend hike, generic competition, and a 54% FCF ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果